Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022 

Dr. Alexander M. Lesokhin Discusses Initial Safety Results for MagnetisMM-3: Phase 2 Trial of Elranatamab (BCMA)-CD3 Bispecific Antibody in RRMM Patients 

Abstract Title: 

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). 

What is the purpose of this trial?  

MagnetisMM-3 is an open-label, multicenter, non-randomized, phase 2 study to evaluate the safety and efficacy of elranatamab monotherapy in relapsed/refractory multiple myeloma (RRMM) patients. Initial safety results are presented.  

The purpose of the study is to evaluate whether single-agent elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and B cell maturation antigen (BCMA)-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.  

In this video: 

Dr. Alexander M. Lesokhin (Memorial Sloan Kettering Cancer Center—New York, NY) discusses initial safety results for MagnetisMM-3: Phase 2 Trial of elranatamab (BCMA)-CD3 bispecific antibody in RRMM patients. 

Conclusion: 

Preliminary results of MagnetisMM-3 in RRMM patients with no prior BCMA-targeted treatment suggest that 76 mg QW elranatamab with a 2-step-up priming regimen is well tolerated, with no Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. 

Clinical trial information: NCT04649359